🇺🇸 armodafinil 150 mg in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 10

Most-reported reactions

1. Abdominal Pain Upper — 1 report (10%)
2. Decreased Appetite — 1 report (10%)
3. Gastrointestinal Disorder — 1 report (10%)
4. Headache — 1 report (10%)
5. Hypersensitivity — 1 report (10%)
6. Malaise — 1 report (10%)
7. Product Colour Issue — 1 report (10%)
8. Product Odour Abnormal — 1 report (10%)
9. Product Storage Error — 1 report (10%)
10. Product Taste Abnormal — 1 report (10%)

Source database →

Frequently asked questions

Is armodafinil 150 mg approved in United States?

armodafinil 150 mg does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for armodafinil 150 mg in United States?

Alliance for Clinical Trials in Oncology is the originator. The local marketing authorisation holder may differ — check the official source linked above.